Annual hazard rates of recurrence for breast cancer after primary therapy

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2738-2746

  Saphner, T ^a   Tormey, D C ^a   Gray, R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0029759541     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2738     Document Type: Article

References (21)

1. Adair F, Berg J, Joubert L, et al: Long-term follow-up of breast cancer patients: The 30-year report. Cancer 33:1145-1150, 1974
2. Brinkley D, Haybittle JL: The curability of breast cancer. Lancet 2:95-97, 1975
3. Duncan W, Kerr GR: The curability of breast cancer. Br Med J 2:781-783, 1976
4. Langlands AO, Pocock SJ, Kerr GR, et al: Long-term survival - of patients with breast cancer: A study of the curability of the disease. Br Med J 2:1247-1251, 1979
5. Hibberd AD, Horwood LJ, Wells JE: Long term prognosis of women with breast cancer in New Zealand: Study of survival to 30 years. Br Med J 286:1777-1779, 1983
6. Brinkley D, Haybittle JL: Long-term survival of women with breast cancer. Lancet 1:1118, 1984 (letter)
7. Rutqvist LE, Wallgren A, Nilsson B: Is breast cancer a curable diseases? A study of 14,731 women with breast cancer from the cancer registry of Norway. Cancer 53:1793-1800, 1984
8. Rutqvist LE, Wallgren A: Long-term survival of 458 young breast cancer patients. Cancer 55:658-665, 1985
9. 0) breast carcinoma. J Clin Oncol 7:355-366, 1989
10. Joensuu H, Toikkanen S: Cured of breast cancer? J Clin Oncol 13:62-69, 1995
11. Quiet CA, Ferguson DJ, Weichselbaum RR, et al: Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J Clin Oncol 13:1144-1151, 1995
12. Tormey DC, Gray R, Gilchrist K, et al: Adjuvant chemohormonal therapy with cyclophosphamide. methotrexate, fluorouracil, prednisone (CMFP) or CMFP plus tamoxifen compared to CMF for premenopausal breast cancer patients-An Eastern Cooperative Oncology Group trial. Cancer 65:200-206, 1990
13. Taylor SG, Knuiman MW, Sleeper LA, et al: Six-year results of Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node positive breast cancer. J Clin Oncol 7:879-889, 1989
14. Cummings FJ, Gray R, Tormey DC, et al: Adjuvant tamoxifen versus placebo in elderly women with node positive breast cancer: Long-term follow-up and causes of death. J Clin Oncol 11:29-35, 1993
15. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high-risk node negative breast cancer: An intergroup study. N Engl J Med 320:485-490, 1989
16. Olson JE, Neuberg D, Pandya K. et al: The management of resectable stage III breast cancer: The Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 8:23, 1989 (abstr)
17. Falkson HC, Gray R, Wolberg WH, et al: Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: An Eastern Cooperative Oncology Group phase III study. J Clin Oncol 8:599-607, 1990
18. Tormey DC, Gray R, Abeloff MD, et al: Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial. J Clin Oncol 10:1848-1856, 1992
19. Holford TR: Life tables with concomitant information. Biometrics 32:587-597, 1976
20. Mantel N: Evaluation of survival data in two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1976
21. Mueller CB, Jeffries W: Cancer of the breast: Its outcome as measured by the rated of dying and causes of death. Ann Surg 182:334-341, 1975